Bioorthogonal-catalytic artificial antigen-presenting cell demonstrates improved antitumor response, suggesting advancements in immunomodulation and chemotherapy.
A biomimetic artificial antigen-presenting cell-based bioorthogonal catalyst is developed. By imitating dendritic cell functions, LNP-Fe@dcM mediates a dual-mode antitumor response via prodrug activation and immunomodulation.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: